# Journey Medical Corp: Form 10-Q for the period ended Sep 30, 2023

- Company: [Journey Medical Corp](/companies/derm.md) (CIK 1867066)
- Form: 10-Q
- Filed: 2023-11-13
- Accepted by EDGAR: Nov 9, 2023, 19:55 ET
- Period: 2023-09-30
- Accession: 0001410578-23-002335
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1867066/000141057823002335/derm-20230930x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1867066/000141057823002335/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2023-07-01 to 2023-09-30 | $15.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2023-01-01 to 2023-09-30 | $44.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2023-07-01 to 2023-09-30 | $6.4m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2023-01-01 to 2023-09-30 | $20.6m | us-gaap:CostOfRevenue |
| Research and development | 3 months, 2023-07-01 to 2023-09-30 | $2.2m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2023-01-01 to 2023-09-30 | $6.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2023-07-01 to 2023-09-30 | $8.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2023-01-01 to 2023-09-30 | $34.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2023-07-01 to 2023-09-30 | $17.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2023-01-01 to 2023-09-30 | $31.0k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2023-07-01 to 2023-09-30 | $268.0k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2023-01-01 to 2023-09-30 | $1.7m | us-gaap:InterestExpense |
| Income tax | 3 months, 2023-07-01 to 2023-09-30 | $95.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2023-01-01 to 2023-09-30 | $95.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2023-07-01 to 2023-09-30 | $16.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2023-01-01 to 2023-09-30 | −$1.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2023-07-01 to 2023-09-30 | $0.80 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2023-01-01 to 2023-09-30 | −$0.09 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2023-07-01 to 2023-09-30 | $0.91 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2023-01-01 to 2023-09-30 | −$0.09 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2023-07-01 to 2023-09-30 | 21,034,758 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2023-01-01 to 2023-09-30 | 18,078,437 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2023-01-01 to 2023-09-30 | $21.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2023-01-01 to 2023-09-30 | $5.0m | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | at 2023-09-30 | $24.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-09-30 | $44.7m | us-gaap:AssetsCurrent |
| Total assets | at 2023-09-30 | $65.9m | us-gaap:Assets |
| Current liabilities | at 2023-09-30 | $48.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-09-30 | $48.5m | us-gaap:Liabilities |
| Long-term debt | at 2023-09-30 | $0 | us-gaap:LongTermDebt |
| Shareholders' equity | at 2023-09-30 | $17.4m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 40,763 characters.

*Certain matters discussed in this report may constitute forward-looking statements for purposes of the Securities Act of 1933, as amended (the “Securities Act”), and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the future results, performance or achievements expressed or implied by such forward-looking statements. The words “anticipate,” “believe,” “estimate,” “may,” “expect,” “will,” “could,” “project,” “should,” “intend” and similar expressions are generally intended to identify forward-looking statements. Our actual results may differ materially from the results anticipated in or implied by these forward-looking statements due to a variety of factors, including, without limitation:*

- *the fact that our products and product candidates are subject to time and cost intensive regulation and clinical testing and as a result, may never be successfully developed or commercialized;*
- *a substantial portion of our sales derive from products that may become subject to third-party generic competition, the introduction of new competitor products, or an increase in market share of existing competitor products, any of which could have a significant adverse impact on our operating income;*
- *we operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative or executive action may have on our operations;*
- *our revenue is dependent mainly upon sales of our dermatology products and any setback relating to the sale of such products could impair our operating results;*
- *competition could limit our products’ commercial opportunity and profitability, including competition from manufacturers of generic versions of our products;*
- *the risk that our products do not achieve broad market acceptance, including by government and third-party payors;*
- *our reliance third parties for several aspects of our operations;*
- *our dependence on our ability to identify, develop, and acquire or in-license products and integrate them into our operations, at which we may be unsuccessful;*
- *the dependence of the success of our business, including our ability to finance our company and generate additional revenue, on the successful development and regulatory approval of the DFD-29 product candidate and any future product candidates that we may develop, in-license or acquire;*
- *clinical drug development is very expensive, time consuming, and uncertain and our clinical trials may fail to adequately demonstrate the safety and efficacy of our current or any future product candidates;*
- *our competitors could develop and commercialize products similar or identical to ours;*
- *risks related to the protection of our intellectual property and our potential inability to maintain sufficient patent protection for our technology and products;*
- *our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our or our third parties’ cybersecurity;*
- *the substantial doubt expressed about our ability to continue as a going concern;*
- *the effects of major public health issues, epidemics or pandemics on our product revenues and any future clinical trials;*
- *our potential need to raise additional capital;*
- *Fortress controls a voting majority of our common stock, which could be detrimental to our other shareholders;*
- *and the risks described in under the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Form 10-K”).*

*The forward-looking statements contained in this report reflect our views and assumptions as of the effective date of this report. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us. Except as required by law, we assume no responsibility for updating any forward-looking statements.*

*We qualify all of our forward-looking statements by these cautionary statements. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.*

### Overview

We are a commercial-stage pharmaceutical company founded in October 2014 that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions. Our current portfolio includes eight branded and two authorized generic prescription drugs for dermatological conditions that are actively marketed in the U.S. We are managed by experienced life science executives with a track record of creating value for their stakeholders and bringing novel medicines to the market, enabling patients to experience increased quality of life and physicians and other licensed medical professionals to provide better care for their patients. We aim to acquire rights to future products by licensing or otherwise acquiring an ownership interest in, funding the research and development of, and eventually commercializing, the products through our field sales force.

### Recent Corporate Highlights

On August 31, 2023, we entered into the New License Agreement with Maruho, whereby we granted an exclusive license to Maruho to develop and commercialize Qbrexza® for the treatment of primary axillary hyperhidrosis in the Territory. Under the terms of the New License Agreement, Maruho paid $19.0 million as a non-refundable upfront payment. Maruho is also obligated to make royalty payments to us related to sales of the product in the Territory equal to the corresponding rate payable by us to Dermira under the asset purchase agreement between us and Dermira.

In July 2023, we paid off the entire $10.0 million outstanding balance on the EWB term loan. We have no further obligations to EWB or outstanding bank debt.

In July 2023, we announced positive topline data from our two DFD-29 Phase 3 clinical trials for the treatment of papulopustular rosacea. The Phase 3 clinical trials achieved the co-primary and all secondary endpoints and subjects completed the 16-week treatment with no significant safety issues. DFD-29 demonstrated statistical superiority over both the standard of care, Oracea® capsules, and placebo for Investigator’s Global Assessment treatment success and the reduction in the total inflammatory lesion count in both studies. We plan to file an NDA to the U.S. Food and Drug Administration for DFD-29 around the end of 2023 and expect potential approval from the FDA in the second half of 2024.

### Critical Accounting Polices and Uses of Estimates

Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States. Applying these principles requires our judgment in determining the appropriateness of acceptable accounting principles and methods of application in diverse and complex economic activities. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of revenues, expenses, assets and liabilities, and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and other assumptions that we believe are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

For a discussion of our critical accounting estimates, see the section of the 2022 Form 10-K titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Use of Estimates.” There were no material changes in our critical accounting estimates or accounting policies from December 31, 2022.

### Accounting Pronouncements

During the nine-month period ended September 30, 2023, there were no new accounting pronouncements or updates to recently issued accounting pronouncements disclosed in the 2022 Form 10-K that are expected to materially affect the Company’s present or future financial statements.

### Emerging Growth Company and Smaller Reporting Company Status

We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, emerging growth companies can delay the adoption of new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. Other exemptions and reduced reporting requirements under the JOBS Act for emerging growth companies include presentation of only two years of audited financial statements in our annual reports on Form 10-K, an exemption from the requirement to provide an auditor’s report on internal controls over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, as amended, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation and less extensive disclosure about our executive compensation arrangements. We have elected to use the extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that (i) we are no longer an emerging growth company or (ii) we affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act.

We are also a “smaller reporting company,” meaning that either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) the market value of our shares held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our shares held by non-affiliates is less than $700 million. As a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K, have reduced disclosure obligations regarding executive compensation, and smaller reporting companies are permitted to delay adoption of certain recent accounting pronouncements discussed in Note 2 to our consolidated financial statements in this report on Form 10-Q.

### Results of Operations

The following table summarizes our results of operations for the three-month periods ended September 30, 2023 and 2022:

### Comparison of the Three-Month Periods Ended September 30, 2023 and 2022

*($ in thousands, except per share data)*

| ​ ​ Revenue: | ​ ​ ​ | ​ ​ Three-Month Periods Ended September 30, 2023 ​ ​ | ​ ​ | ​ ​ 2022 ​ ​ | ​ ​ ​ | ​ ​ Change $% ​ ​ | ​ ​ | ​ ​ ​ ​ |
| --- | --- | --- | --- | --- | --- | --- | --- | ---: |
| Product revenue, net |  | $15,279 |  | $16,043 | ​ | $(764) | ​ | -5% |
| Other revenue | ​ | ​ 19,260 | ​ | ​ 73 | ​ | ​ 19,187 | ​ | 26284% |
| Total revenue | ​ | ​ 34,539 | ​ | ​ 16,116 | ​ | ​ 18,423 | ​ | 114% |
| ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| **Operating expenses** |  | ​ |  | ​ | ​ | ​ | ​ | ​ |
| Cost of goods sold – product revenue |  | ​ 6,429 |  | ​ 7,221 | ​ | ​ (792) | ​ | -11% |
| Research and development |  | ​ 2,229 |  | ​ 2,812 | ​ | ​ (583) | ​ | -21% |
| Selling, general and administrative |  | ​ 8,636 |  | ​ 15,575 | ​ | ​ (6,939) | ​ | -45% |
| Total operating expenses |  | ​ 17,294 |  | ​ 25,608 | ​ | ​ (8,314) | ​ | -32% |
| Income (loss) from operations |  | ​ 17,245 |  | ​ (9,492) | ​ | ​ 26,737 | ​ | -282% |
| ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| **Other expense (income)** |  | ​ ​ |  | ​ | ​ | ​ | ​ | ​ |
| Interest income |  | ​ (8) |  | ​ (3) | ​ | ​ (5) | ​ | 167% |
| Interest expense | ​ | ​ 268 | ​ | ​ 559 | ​ | ​ (291) | ​ | -52% |
| Foreign exchange transaction losses | ​ | ​ 101 | ​ | ​ 22 | ​ | ​ 79 | ​ | 359% |
| Total other expense (income) |  | ​ 361 |  | ​ 578 | ​ | ​ (217) | ​ | -38% |
| **Income (loss) before income taxes** |  | **​** **16,884** |  | **​** **(10,070)** | **​** | **​** **26,954** | **​** | **-268%** |
| ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Income tax expense |  | ​ 95 |  | ​ 10 | ​ | ​ 85 | ​ | 850% |
| **Net income (loss)** | **​** | $16,789 | **​** | $(10,080) | **​** | **​** **26,869** | **​** | **-267%** |

### Revenues

The following table reflects our net product revenue for the three-month periods ended September 30, 2023 and 2022:

*($ in thousands)*

| ​ ​ ​ | ​ ​ ​ | ​ ​ Three-Month Periods Ended September 30, 2023 | ​ | ​ ​ 2022 | ​ ​ ​ | ​ ​ ​ ​ Change $% | ​ ​ | ​ ​ ​ |
| --- | --- | ---: | --- | ---: | --- | --- | --- | ---: |
| Qbrexza® | ​ | $5,865 | ​ | $6,265 | ​ | $(400) | ​ | -6% |
| Accutane® | ​ | ​ 4,882 | ​ | ​ 4,121 | ​ | ​ 761 | ​ | 18% |
| Amzeeq® | ​ | ​ 2,336 | ​ | ​ 1,161 | ​ | ​ 1,175 | ​ | 101% |
| Zilxi® | ​ | ​ 681 | ​ | ​ 554 | ​ | ​ 127 | ​ | 23% |
| Targadox® | ​ | 929 | ​ | 1,168 | ​ | ​ (239) | ​ | -20% |
| Exelderm® | ​ | 764 | ​ | 1,001 | ​ | ​ (237) | ​ | -24% |
| Ximino® | ​ | (199) | ​ | 1,773 | ​ | ​ (1,972) | ​ | -111% |
| Luxamend® | ​ | ​ 21 | ​ | ​ — | ​ | ​ 21 | ​ | 100% |
| **Total net product revenue** | **​** | **$15,279** | **​** | **$16,043** | **​** | **$(764)** | **​** | **-5%** |

Total net product revenues decreased by $0.8 million, or 5.0%, to $15.3 million for the three-month period ended September 30, 2023, from $16.0 million for the three-month period ended September 30, 2022. The decrease is primarily due to lower net revenue from Ximino resulting from lower unit volumes due to the winding down of the product during the third quarter, along with higher coupon redemption volumes. We discontinued selling Ximino on September 29, 2023. The decrease was partially offset by an increase in net product revenues from Accutane, Amzeeq and Zilxi due to our continued sales and marketing emphasis on these products as well as optimization of our coupon processing access program for our specialty pharmaceutical customers. Qbrexza unit volumes slightly decreased from period-to-period resulting in a $0.4 million decrease in net sales. Our four core products, Qbrexza, Accutane, Amzeeq and Zilxi, all acquired and launched since 2022, represent approximately 90%, or $13.8 million, of our total net product revenue for the three-month period ended September 30, 2023.

### Other revenue

*($ in thousands)*

| ​ ​ | ​ ​ | ​ ​ Three-Month Periods Ended September 30, 2023 | ​ | ​ ​ 2022 | ​ ​ | ​ ​ Change $% | ​ | ​ ​ ​ |
| --- | --- | ---: | --- | ---: | --- | ---: | --- | ---: |
| Non-refundable upfront payment from Maruho | ​ | $19,000 | ​ | $— | ​ | $19,000 | ​ | 100% |
| Royalties on sales of Rapifort® Wipes 2.5% | ​ | ​ 260 | ​ | ​ 73 | ​ | ​ 187 | ​ | 256% |
| **Total other revenue** | ​ | **$19,260** | ​ | **$73** | ​ | **$19,187** | ​ | 26284% |

Other revenues increased approximately $19.2 million, to $19.3 million for the three-month period ended September 30, 2023, from $73,000 for the three-month period ended September 30, 2022. Other revenue in the current period includes a $19.0 million non-refundable upfront payment from Maruho under the New License Agreement. In addition, royalties on sales of Rapifort® Wipes 2.5%. in Japan were $260,000 for the three-month period ended September 30, 2023 as compared to $73,000 for the three-month period ended September 30, 2022. Sales of Rapifort® in Japan will no longer be subject to a royalty after October 1, 2023 in accordance with the Second A&R License Agreement.

### Gross-to-Net Sales Accruals

We record gross-to-net sales accruals for chargebacks, distributor service fees, prompt pay discounts, sales returns, coupons, managed care rebates, government rebates, and other allowances customary to the pharmaceutical industry.

Gross-to-net sales accruals and the balance in the related allowance accounts for the three-month periods ended September 30, 2023 and 2022, were as follows:

*($’s in thousands)*

| ​ ​ ​ | ​ ​ ​ | ​ ​ Chargebacks and other allowances | ​ ​ ​ | ​ ​ ​ Distributor Service Fees | ​ ​ ​ | ​ ​ ​ ​ Prompt Pay Discounts | ​ ​ ​ | ​ ​ ​ ​ ​ ​ Returns | ​ ​ ​ | ​ ​ ​ ​ ​ ​ Coupons | ​ ​ ​ | ​ ​ Managed Care Rebates | ​ ​ ​ | ​ ​ ​ ​ Gov’t Rebates | ​ ​ ​ | ​ ​ ​ ​ ​ ​ Total |
| --- | --- | ---: | --- | ---: | --- | ---: | --- | ---: | --- | ---: | --- | ---: | --- | ---: | --- | ---: |
| **Balance as of June 30, 2023** | ​ | **$265** | **​** | **$879** | **​** | **$192** | **​** | **$4,545** | **​** | **$4,092** | **​** | **$3,732** | **​** | **$3,417** | **​** | **$17,122** |
| Current provision related to sales in the current period | ​ | ​ 230 | ​ | 1,283 | ​ | ​ 215 | ​ | 497 | ​ | 20,604 | ​ | 5,478 | ​ | 519 | ​ | 28,826 |
| Checks/credits issued to third parties | ​ | ​ (403) | ​ | (1,348) | ​ | ​ (261) | ​ | (519) | ​ | (22,926) | ​ | (6,266) | ​ | (3,560) | ​ | (35,283) |
| **Balance as of September 30, 2023** | ​ | **$92** | **​** | **$814** | **​** | **$146** | **​** | **$4,523** | **​** | **$1,770** | **​** | **$2,944** | **​** | **$376** | **​** | **$10,665** |

*($’s in thousands)*

| ​ ​ ​ | ​ ​ ​ | ​ ​ Chargebacks and other allowances | ​ ​ ​ | ​ ​ ​ Distributor Service Fees | ​ ​ ​ | ​ ​ ​ ​ Prompt Pay Discounts | ​ ​ ​ | ​ ​ ​ ​ ​ ​ Returns | ​ ​ ​ | ​ ​ ​ ​ ​ ​ Coupons | ​ ​ ​ | ​ ​ Managed Care Rebates | ​ ​ ​ | ​ ​ ​ ​ Gov’t Rebates | ​ ​ ​ | ​ ​ ​ ​ ​ ​ Total |
| --- | --- | ---: | --- | ---: | --- | ---: | --- | ---: | --- | ---: | --- | ---: | --- | ---: | --- | ---: |
| **Balance as of June 30, 2022** | ​ | **$273** | **​** | **$933** | **​** | **$194** | **​** | **$2,727** | **​** | **$2,499** | **​** | **$3,191** | **​** | **$1,218** | **​** | **$11,035** |
| Current provision related to sales in the current period | ​ | ​ 829 | ​ | ​ 1,515 | ​ | ​ 290 | ​ | ​ 1,706 | ​ | ​ 25,801 | ​ | ​ 6,897 | ​ | ​ 639 | ​ | ​ 37,677 |
| Checks/credits issued to third parties | ​ | ​ (814) | ​ | ​ (1,522) | ​ | ​ (280) | ​ | ​ (1,471) | ​ | ​ (26,348) | ​ | ​ (6,339) | ​ | ​ (928) | ​ | ​ (37,702) |
| **Balance as of September 30, 2022** | ​ | **$288** | **​** | **$926** | **​** | **$204** | **​** | **$2,962** | **​** | **$1,952** | **​** | **$3,749** | **​** | **$929** | **​** | **$11,010** |

Gross-to-net sales accruals were $10.7 million at September 30, 2023, compared to $17.1 million at June 30, 2023, a decrease of $6.4 million. The decrease is primarily due to the termination of our Medicaid National Drug Rebate and Pharmaceutical Pricing Agreements in the third quarter. In addition, our reserve for coupons decreased as a result of our efforts to reduce overall coupon expense and make improvements to our programs, including increasing patient out-of-pocket costs for certain products and changing our overall mix of coupon related business to reduce the volume of higher dollar claims. Additionally, our managed care reserve decreased due to lower unit volumes and product mix of claims.

### Cost of Goods Sold

Cost of goods sold decreased by $0.8 million, or 11%, to $6.4 million for the three-month period ended September 30, 2023, from $7.2 million for the three-month period ended September 30, 2022. The decrease is primarily due to the contractual decrease in our Qbrexza royalty from period to period, accounting for $0.6 million of the decrease, as well as lower sales of this product during the period.

### Research and Development

Research and Development expense decreased by $0.6 million, or 21%, to $2.2 million for the three-month period ended September 30, 2023, from $2.8 million for the three-month period ended September 30, 2022. The decrease is related to lower clinical trial expenses to develop our DFD-29 product as the project winds down.

### Selling, General and Administrative

Selling, general and administrative (“SG&A”) expenses decreased by $6.9 million, or 45%, to $8.6 million for the three-month period ended September 30, 2023, from $15.6 million for the three-month period ended September 30, 2022. The decrease is mainly due to our expense reduction efforts primarily in sales and marketing and other SG&A areas, including a headcount reduction to our salesforce, designed to improve operational efficiencies, optimize expenses and reduce overall costs.

### Interest Expense

Interest expense decreased by $0.3 million to $0.3 million for the three-month period ended September 30, 2023, from $0.6 million for the three-month period ended September 30, 2022. The decrease is primarily attributable to the repayment of the EWB Facility term loan in July 2023, which ended our obligation to pay interest on any borrowed money.

### Comparison of the Nine-Month Periods Ended September 30, 2023 and 2022

*($in thousands, except per share data)*

| ​ ​ Revenue: | ​ ​ ​ | ​ ​ Nine-Month Periods Ended September 30, 2023 ​ | ​ | ​ ​ 2022 ​ | ​ ​ ​ | ​ ​ Change $% | ​ ​ | ​ ​ ​ |
| --- | --- | ---: | --- | ---: | --- | ---: | --- | ---: |
| Product revenue, net | ​ | $44,405 | ​ | $55,074 | ​ | $(10,669) | ​ | -19% |
| Other revenue | ​ | 19,519 | ​ | 2,629 | ​ | 16,890 | ​ | 642% |
| Total revenue | ​ | 63,924 | ​ | 57,703 | ​ | 6,221 | ​ | 11% |
| ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| **Operating expenses** | ​ |  | ​ |  | ​ |  | ​ | ​ |
| Cost of goods sold – product revenue | ​ | 20,645 | ​ | 23,057 | ​ | (2,412) | ​ | -10% |
| Research and development | ​ | 6,036 | ​ | 6,687 | ​ | (651) | ​ | -10% |
| Selling, general and administrative | ​ | 34,069 | ​ | 45,481 | ​ | (11,412) | ​ | -25% |
| Loss on impairment of intangible assets | ​ | 3,143 | ​ | — | ​ | 3,143 | ​ | 100% |
| Total operating expenses | ​ | 63,893 | ​ | 75,225 | ​ | (11,332) | ​ | -15% |
| Income (loss) from operations | ​ | 31 | ​ | (17,522) | ​ | 17,553 | ​ | -100% |
| ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| **Other expense (income)** | ​ |  | ​ |  | ​ |  | ​ | ​ |
| Interest income | ​ | (209) | ​ | (10) | ​ | (199) | ​ | 1990% |
| Interest expense | ​ | 1,674 | ​ | 1,402 | ​ | 272 | ​ | 19% |
| Foreign exchange transaction losses | ​ | 181 | ​ | 22 | ​ | 159 | ​ | 723% |
| Total other expense (income) | ​ | 1,646 | ​ | 1,414 | ​ | 232 | ​ | 16% |
| **Loss before income taxes** | **​** | **(1,615)** | **​** | **(18,936)** | **​** | **17,321** | ​ | **-91%** |
| ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Income tax expense | ​ | 95 | ​ | 50 | ​ | 45 | ​ | 90% |
| **Net loss** | ​ | **$(1,710)** | **​** | **$(18,986)** | **​** | **​** **17,276** | **​** | **-91%** |

### Revenues

The following table reflects our net product revenue for the nine-month periods ended September 30, 2023 and 2022:

*($in thousands)*

| ​ ​ ​ | ​ ​ ​ | ​ ​ Nine-Month Periods Ended September 30, 2023 | ​ | ​ ​ 2022 | ​ ​ ​ | ​ ​ ​ ​ Change $% | ​ ​ | ​ ​ ​ |
| --- | --- | ---: | --- | ---: | --- | ---: | --- | ---: |
| Qbrexza® | ​ | $18,038 | ​ | $19,752 | ​ | $(1,714) | ​ | -9% |
| Accutane® | ​ | 15,109 | ​ | 14,228 | ​ | 881 | ​ | 6% |
| Amzeeq® | ​ | 4,904 | ​ | 5,892 | ​ | (988) | ​ | -17% |
| Zilxi® | ​ | 1,567 | ​ | 1,851 | ​ | (284) | ​ | -15% |
| Targadox® | ​ | 2,386 | ​ | 6,558 | ​ | (4,172) | ​ | -64% |
| Exelderm® | ​ | 1,813 | ​ | 3,018 | ​ | (1,205) | ​ | -40% |
| Ximino® | ​ | 567 | ​ | 3,775 | ​ | (3,208) | ​ | -85% |
| Luxamend® | ​ | ​ 21 | ​ | ​ — | ​ | ​ 21 | ​ | 100% |
| **Total net product revenue** | **​** | **$44,405** | **​** | **$55,074** | **​** | **$(10,669)** | **​** | **-19%** |

Total net product revenues decreased by $10.7 million, or 19.0%, to $44.4 million for the nine-month period ended September 30, 2023, from $55.1 million for the nine-month period ended September 30, 2022. The decrease is primarily due to lower unit volumes from our legacy products, Targadox, Ximino and Exelderm, substantially driven by continued generic competition for Targadox. In addition, during the third quarter of 2023, we wound down and discontinued selling Ximino on September 29, 2023. The nine-month period ended September 30, 2023 was also negatively impacted by higher gross-to-net allowances, that occurred in the first quarter, for coupon rebates as a result of higher deductible rate resets, higher managed care rebates due to higher managed care program costs, higher-than-anticipated returns from the Dermira product lots purchased in 2021, and higher government rebates from increases in state rebate programs impacting the net revenues of our four core growth products, Qbrexza, Accutane, Amzeeq and Zilxi.

### Other revenue

*($in thousands)*

| ​ ​ | ​ | ​ ​ Nine-Month Periods Ended September 30, 2023 | ​ | ​ ​ 2022 | ​ | ​ ​ Change $% | ​ | ​ ​ |
| --- | --- | ---: | --- | ---: | --- | ---: | --- | ---: |
| Non-refundable upfront payment from Maruho | ​ | $19,000 |  | $— |  | $19,000 | ​ | 100% |
| Net milestone payment from Maruho | ​ | ​ — | ​ | ​ 2,500 | ​ | ​ (2,500) | ​ | -100% |
| Royalties on sales of Rapifort® Wipes 2.5% | ​ | ​ 519 | ​ | ​ 129 | ​ | ​ 390 | ​ | 302% |
| **Total other revenue** | **​** | **$19,519** |  | **$2,629** |  | **$16,890** | **​** | **642%** |

Other revenues increased approximately $16.9 million, to $19.5 million for the nine-month period ended September 30, 2023, from $2.6 million for the nine-month period ended September 30, 2022. Other revenue for the nine-month period ended September 30, 2023 includes a $19.0 million non-refundable upfront payment from Maruho under the New License Agreement. In addition, royalties on sales of Rapifort® Wipes 2.5%. in Japan were $0.5 million for the nine-month period ended September 30, 2023 as compared to $0.1 million for the three month period ended September 30, 2022. Other revenue for the nine-month period ended September 30, 2022 includes a net $2.5 million milestone payment from Maruho. In January 2022, Maruho received manufacturing and marketing approval in Japan for Rapifort® Wipes 2.5% (Japanese equivalent to U.S. FDA approved QBREXZA®), for the treatment of primary axillary hyperhidrosis, triggering the one-time net payment. Sales of Rapifort® in Japan will no longer be subject to a royalty after October 1, 2023 in accordance with the Second A&R License Agreement.

### Gross-to-Net Sales Accruals

We record gross-to-net sales accruals for chargebacks, distributor service fees, prompt pay discounts, sales returns, coupons, managed care rebates, government rebates, and other allowances customary to the pharmaceutical industry.

Gross-to-net sales accruals and the balance in the related allowance accounts for the nine-month period ended September 30, 2023 and 2022, were as follows:

*($'s in thousands)*

| ​ ​ ​ ​ | ​ ​ ​ ​ | ​ ​ Chargebacks and other allowances | ​ ​ ​ ​ | ​ ​ ​ ​ Distributor Service Fees | ​ ​ ​ ​ | ​ ​ ​ ​ Prompt Pay Discounts | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ Returns | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ Coupons | ​ ​ ​ ​ | ​ ​ ​ ​ Managed Care Rebates | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ Gov't Rebates | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ Total |
| --- | --- | ---: | --- | ---: | --- | ---: | --- | ---: | --- | ---: | --- | ---: | --- | ---: | --- | ---: |
| **Balance as of December 31, 2022** | **​** | **$253** | **​** | **$929** | **​** | **$207** | **​** | **$3,689** | **​** | **$1,696** | **​** | **$3,594** | **​** | **$1,010** | **​** | **$11,378** |
| Current provision related to sales in the current period | ​ | 1,601 | ​ | 4,181 | ​ | 763 | ​ | 4,670 | ​ | 74,298 | ​ | 16,892 | ​ | 4,860 | ​ | 107,265 |
| Checks/credits issued to third parties | ​ | (1,762) | ​ | (4,296) | ​ | (824) | ​ | (3,836) | ​ | (80,391) | ​ | (17,542) | ​ | (5,494) | ​ | (114,145) |
| Reclass coupon vendor deposit to accounts payable | ​ | ​ — | ​ | ​ — | ​ | ​ — | ​ | ​ — | ​ | ​ 6,167 | ​ | ​ — | ​ | ​ — | ​ | ​ 6,167 |
| **Balance as of September 30, 2023** | **​** | **$92** | **​** | **$814** | **​** | **$146** | **​** | **$4,523** | **​** | **$1,770** | **​** | **$2,944** | **​** | **$376** | **​** | **$10,665** |

*($'s in thousands)*

| ​ ​ ​ ​ | ​ ​ ​ ​ | ​ ​ Chargebacks and other allowances | ​ ​ ​ ​ | ​ ​ ​ ​ Distributor Service Fees | ​ ​ ​ ​ | ​ ​ ​ ​ Prompt Pay Discounts | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ Returns | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ Coupons | ​ ​ ​ ​ | ​ ​ ​ ​ Managed Care Rebates | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ Gov't Rebates | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ Total |
| --- | --- | ---: | --- | ---: | --- | ---: | --- | ---: | --- | ---: | --- | ---: | --- | ---: | --- | ---: |
| **Balance as of December 31, 2021** | **​** | **$622** | **​** | **$791** | **​** | **$197** | **​** | **$3,240** | **​** | **$4,992** | **​** | **$3,492** | **​** | **$690** | **​** | **$14,024** |
| Current provision related to sales in the current period | ​ | 1,941 | ​ | 4,367 | ​ | 816 | ​ | 3,996 | ​ | 92,330 | ​ | 17,131 | ​ | 2,395 | ​ | 122,976 |
| Checks/credits issued to third parties | ​ | (2,275) | ​ | (4,232) | ​ | (809) | ​ | (4,274) | ​ | (95,370) | ​ | (16,874) | ​ | (2,156) | ​ | (125,990) |
| **Balance as of September 30, 2022** | **​** | **$288** | **​** | **$926** | **​** | **$204** | **​** | **$2,962** | **​** | **$1,952** | **​** | **$3,749** | **​** | **$929** | **​** | **$11,010** |

Gross-to-net sales accruals were $10.7 million at September 30, 2023, compared to $11.4 million at December 31, 2022, a decrease of $0.7 million. The decrease is primarily due to the decrease in gross sales for the nine-month period ended September 30, 2023. In addition, we terminated our Medicaid National Drug Rebate and Pharmaceutical Pricing Agreements in the third quarter. The decrease is partially offset by an increase in the provision for returns for Qbrexza for actual returns experience that occurred in the first quarter.

### Cost of Goods Sold

Cost of goods sold decreased by $2.4 million, or 10%, to $20.6 million for the nine-month period ended September 30, 2023, from $23.1 million for the nine-month period ended September 30, 2022. The decrease is mainly due to lower than-prior-year product royalties driven by lower sales, including a contractual decrease in the Qbrexza royalty percentage from the prior year period.

### Research and Development

Research and development expense decreased by $0.7 million, or 10%, to $6.0 million for the nine-month period ended September 30, 2023, from $6.7 million for the nine-month period ended September 30, 2022. The decrease is related to lower clinical trial expenses to develop our DFD-29 product as the project winds down.

### Selling, General and Administrative

SG&A expenses decreased by $11.4 million, or 25%, to $34.1 million for the nine-month period ended September 30, 2023, from $45.5 million for the nine-month period ended September 30, 2022. The decrease is mainly due to our expense reduction efforts primarily in sales and marketing and other SG&A areas. During the last quarter of 2022, we implemented a cost reduction initiative designed to improve operational efficiencies, optimize expenses and reduce overall costs. The initiative is intended to reduce selling, general, and administrative expenses to better align costs with their revenue-generating capabilities. In connection with the cost reduction initiative, during the last quarter of 2022 and the first two quarters of 2023, we executed a headcount reduction to our salesforce and implemented marketing and other cost cuts.

### Loss on impairment of intangible assets

We recorded a loss on the impairment of intangible assets of $3.1 million in the second quarter of 2023 related to the impairment of the Ximino intangible asset as a result of lower net product revenues and gross profit levels for the Ximino products. We discontinued selling Ximino on September 29, 2023.

### Interest Expense

Interest expense increased by $0.3 million to $1.7 million for the nine-month period ended September 30, 2023, from $1.4 million for the nine-month period ended September 30, 2022.

### Liquidity and Capital Resources

At September 30, 2023, we had $24.7 million in cash and cash equivalents as compared to $32.0 million of cash and cash equivalents at December 31, 2022.

On August 31, 2023, we entered into the New License Agreement with Maruho whereby we granted an exclusive license to Maruho to develop and commercialize Qbrexza® for the treatment of primary axillary hyperhidrosis, in South Korea, Taiwan, Hong Kong, Macau, Thailand, Indonesia, Malaysia, Philippines, Singapore, Vietnam, Brunei, Cambodia, Myanmar and Laos. Under the terms of the New License Agreement, in exchange for the exclusive rights to Qbrexza® in the Territory, Maruho paid $19.0 million to us as a non-refundable upfront payment.

In July 2023, we satisfied all of our outstanding debt obligations to East West Bank by voluntarily repaying the entire $10.0 million outstanding term loan under the EWB facility.

On December 30, 2022, we filed a shelf registration statement on Form S-3 (File No. 333-269079), which was declared effective by the Securities and Exchange Commission (“SEC”) on January 26, 2023. This shelf registration statement covers the offering, issuance, and sale by us of up to an aggregate of $150.0 million of our common stock, preferred stock, debt securities, warrants, and units (the “2022 Shelf”). At September 30, 2023, $150.0 million remains available under the 2022 Shelf. In connection with the 2022 shelf, we entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley Securities, Inc. (“B. Riley”), relating to shares of our common stock. In accordance with the terms of the Sales Agreement, we may offer and sell up to 4,900,000 shares of our common stock, par value $0.0001 per share, from time to time through or to B. Riley acting as our agent or principal.

As a result of increased losses in the latter part of 2022, during the last quarter of 2022, we implemented a cost reduction initiative designed to improve operational efficiencies, optimize expenses, and reduce overall costs. The initiative is intended to reduce selling, general, and administrative expenses to better align costs with revenues being generated. In connection with the cost reduction initiative, during the nine-month period ended September 30, 2023, we executed a headcount reduction to our salesforce and implemented marketing and other cost cuts. As a result of the headcount reduction, the Company recorded a severance obligation of approximately $0.7 million, of which $0.1 million remains to be paid at September 30, 2023.

We regularly evaluate market conditions, our liquidity profile, and financing alternatives, including out-licensing arrangements for our products to enhance our capital structure. We may seek to raise capital through debt or equity financings, to expand our product portfolio, and for other strategic initiatives, which may include sales of securities under our 2022 Shelf or under a new registration statement. We cannot make any assurances that such additional financing will be available to us and, if available, the terms may negatively impact our business and operations. As such, substantial doubt exists about our ability to continue as a going concern for a period of at least twelve months from the date of issuance of the financial statements included in this Quarterly Report on Form 10-Q.

### Cash Flows for the Nine-Month Periods Ended September 30, 2023 and 2022

*($’s in thousands)*

| ​ ​ | ​ ​ | ​ ​ Nine-Month Periods Ended September 30, 2023 | ​ | ​ ​ 2022 | ​ ​ | ​ ​ Increase (Decrease) |
| --- | --- | ---: | --- | ---: | --- | ---: |
| Net cash provided by (used in) operating activities | ​ | $21,760 | ​ | $(9,698) | ​ | $31,458 |
| Net cash used in investing activities | ​ | (5,000) | ​ | (20,000) | ​ | 15,000 |
| Net cash provided by (used in) financing activities | ​ | (24,014) | ​ | 15,508 | ​ | (39,522) |
| **Net change in cash and cash equivalents** | **​** | **​** **(7,254)** | **​** | **​** **(14,190)** | **​** | **​** **6,936** |

#### Operating Activities

Net cash flows provided by operating activities for the nine-month period ended September 30, 2023 increased by $31.5 million to $21.8 million from net cash flows used by operating activities of $9.7 million for the nine-month period ended September 30, 2022. The increase was driven primarily by the Company’s cost reduction efforts as well as the cash payment of $19.0 million received under the New License Agreement with Maruho. This was also driven by vendor, supplier, and other payments in the ordinary course of business, which were generally lower as a result of our expense optimization efforts and accounts receivable collections.

#### Investing Activities

Net cash used in investing activities decreased by $15.0 million from period to period. The nine-month period ended September 30, 2023 reflects the $5.0 million deferred cash payment paid in January 2023 related to the VYNE Product Acquisition. The nine-month period ended September 30, 2022 reflects the upfront $20.0 million payment for the VYNE Product Acquisition.

#### Financing Activities

Net cash flows used in financing activities for nine-month period ended September 30, 2023 increased by $39.5 million to $24.0 million from $15.5 million of cash flows provided by financing activities for the nine-month period ended September 30, 2022. The increase reflects a cash outflow of $20.0 million for the repayment of principal on the EWB term loan and net cash outflows of $2.9 million from the repayment of the EWB revolving line of credit. Net cash provided by financing activities for the nine-month period ended September 30, 2022 reflects net proceeds of $19.8 million from the EWB term loan offset by $3.0 million in payments of the installment notes related to our previously acquired products and $0.8 million for repayment our EWB revolving line of credit.

#### Material Cash Requirements

In the normal course of business, we enter into contractual obligations that contain cash requirements of which the most significant to date include the following:

- Pursuant to our January 2022 agreement with VYNE Therapeutics, Inc. under which we acquired Amzeeq® and Zilxi® (the “VYNE Product Acquisition Agreement”), upon the achievement of net sales milestone payments with respect to the products purchased in the VYNE Product Acquisition Agreement, we are also required to pay contingent consideration consisting of a one-time payment, per product, of $10 million, $20 million, $30 million, $40 million and $50 million upon each product reaching annual sales of $100 million, $200 million, $300 million, $400 million and $500 million, respectively. Each required payment must only be paid one time following the first achievement of the applicable annual sales milestone amount.
- On June 29, 2021, we entered into a license, collaboration, and assignment agreement (the “DFD-29 Agreement”) to obtain the global rights for the development and commercialization of a late-stage development modified release oral minocycline for the treatment of rosacea (“DFD-29”) with Dr. Reddy’s Laboratories, Ltd (“DRL”). Based on the development and commercialization of DFD-29, additional contingent regulatory and commercial milestone payments totaling up to $158.0 million may also become payable. Royalties ranging from ten percent to twenty percent are payable on net sales of the product. Additionally, the Company was required to fund and oversee the Phase 3 clinical trials beginning upon the license of DFD-29 in 2021. The two Phase 3 clinical trials substantially concluded in July 2023 upon the receipt of positive topline results from the trials. The Company expects to pay an approximately $4.0 million filing fee to the FDA upon filing of an Investigational New Drug Application (“NDA”) for DFD-29 around year end 2023. The Company also has an additional contingent milestone payment to DRL upon acceptance of the NDA, the timing of which is uncertain.
- We are contractually obligated to make installment milestone payments of $3.0 million on Ximino, all of which is classified as current as is it due within a year of the September 30, 2023.
- We are contractually obligated to make sales-based royalty payments to Dermira (for Qbrexza), Sun Pharmaceutical Industries (for Exelderm and Ximino) and PuraCap Caribe (for Targadox). Due to the contingent nature of these obligations, the amounts of these payments cannot be reasonably predicted.

## Market risk

As filed, 163 characters.

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.

## Controls and procedures

As filed, 1,322 characters.

#### Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness, as of September 30, 2023, of the design and operation of our disclosure controls and procedures, as such term is defined in Exchange Act Rules 13a-15(e) and 15d-15(e). Based on this evaluation, our principal executive officer and principal financial officer have concluded that, as of such date, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

#### Changes in Internal Control over Financial Reporting

No change in internal control over financial reporting occurred during the most recent quarter with respect to our operations; which materially affected, or is reasonable likely to materially affect, our internal controls over financial reporting.

## Risk factors

As filed, 4,124 characters.

We have disclosed below, as well as under the heading “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “2022 Form 10-K”), supplemented by the disclosure below, a number of risks which may materially affect our business, financial condition or results of operations. You should carefully consider these Risk Factors and other information set forth elsewhere in this Quarterly Report on Form 10-Q. You should be aware that these risk factors and other information may not describe every risk facing our Company. Additional risks and uncertainties not currently known to us may also materially adversely affect our business, financial condition and/or results of operations.

***There is substantial doubt regarding our ability to continue as a going concern. We may need to raise additional funding (which may not be available on acceptable terms to the Company, or at all) and/or to delay, limit or terminate certain of our product development and commercialization efforts or other operations.***

Based on our current business plan and the current amount of cash and cash equivalents available to us, we have concluded that there is substantial doubt regarding our ability to continue as a going concern for a period of at least 12 months from the date of the issuance of the financial statements included in our Quarterly Report on Form 10-Q for the period ended September 30, 2023. In July 2023, we repaid our previously outstanding term loan in full, and therefore our assets are now unencumbered and available to support a new borrowing relationship to provide additional working capital, which we plan to pursue along with our costs reduction initiatives in 2023. In addition to reductions in sales force and marketing expenses, we may also seek to raise capital through additional debt or equity financing, which may include sales of securities under our existing shelf registration statement on Form S-3, including under the Sales Agreement with B. Riley, or under a new registration statement.

Our efforts to raise additional funding may divert our management from its day-to-day activities, which may adversely affect our ability to develop and commercialize our products. In addition, we cannot guarantee that financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our common stock to decline. The sale of additional equity or convertible securities would dilute all of our stockholders. Potential indebtedness, if incurred, would result in increased fixed payment obligations, and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We may be required to relinquish rights to some of our technologies or products or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.

If funding for our operations is not available or not available on terms acceptable to us, our strategic plans may be limited. In addition, in order to address our current funding constraints, we may be required to further revise our business plan and strategy, which may result in us (i) significantly curtailing, delaying or discontinuing our DFD-29 research or development programs or the commercialization of any other products, (ii) selling certain of our assets and/or (iii) being unable to expand our operations or otherwise capitalize on our business opportunities. Such measures may become necessary whether or not we are able to raise additional capital. As a result, our business, financial condition, and results of operations could be materially affected.

Filed Nov 13, 2023.
Source: SEC EDGAR, the filing index for accession 0001410578-23-002335. Last ingested by Listed: Nov 13, 2026, 16:22 ET. No prices; not investment advice.
